Idorsia effectively started its operations after demerging from Actelion on June 15, 2017, and registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange the next day. Today, Idorsia has an experienced team of highly qualified professionals, a full R&D pipeline with 3 Phase 3 programs enrolling the first patients and 1 on-track to commence enrollment later in 2018, state of-the-art facilities, and excellent liquidity – the ideal constellation for bringing successful medicines to the market.
The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Find our latest financial updates, including our financial guidance in the financial overview.
Find out all about Idorsia's liquidity and debt structure.
We provide a full financial archive of our quarterly financial reports and related material.